Articles from Vantive

GLASGOW, Scotland, June 08, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, reports two late-breaking clinical studies indicating HDx therapy (expanded hemodialysis) enabled by the Theranova dialyzer provides similar (statistically non-inferior) all-cause mortality and major cardiovascular outcomes* compared with online hemodiafiltration (OL-HDF).1,2 The randomized controlled MOTheR trial and interim results from the real-world CONCORDIA study were presented at the 63rd European Renal Association (ERA) Congress, held June 3-6, 2026, in Glasgow, Scotland. While both therapies have shown survival benefits over conventional hemodialysis,3,4 HDx therapy offers a practical alternative to OL-HDF because it can be delivered using existing hemodialysis equipment without additional specialized infrastructure or nurse training. HDx therapy utilizes a medium cut-off membrane that efficiently removes large-middle molecules, allowing for filtration closer to that of the natural kidney.5,6,7,8,9,10,11 These large-middle molecules have been linked to inflammation, cardiovascular disease, and other comorbidities in dialysis patients.5-7,11 

New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis

DEERFIELD, Ill., March 31, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, today announced new data presented at the World Congress of Nephrology (WCN), held March 28–31, 2026, in Yokohama, Japan, demonstrating the impact that a coordinated kidney care ecosystem can have on patients’ access to home dialysis and outcomes. International real-world studies highlight the impact of pre-dialysis care, the benefits of collaboration between primary care physicians and nephrologists, and the advantages of remote patient management for home dialysis.

DEERFIELD, Ill., March 23, 2026 (GLOBE NEWSWIRE) -- Vantive, a vital organ therapy company with a 70-year legacy of kidney care innovation, today announced a significant expansion of its U.S. home therapy innovation strategy—including fully-integrated digital capabilities, enhanced patient support programs, and service model improvements designed to reshape how patients experience peritoneal dialysis (PD) at home.

HomeAdvantage is powered by Vantive CONNECT, a suite of digital solutions supporting remote patient monitoring, patient engagement, and data-driven decision-making throughout home dialysis

Collaboration Aims to Expand Peritoneal Dialysis (PD) Access, Enable Greater Connection Between Patients and Care Teams, and Optimize Home Dialysis Care Delivery

Five-year global investment to fuel R&D and manufacturing expansion, supporting development of new technologies and services designed to improve therapy access, care experience and outcomes for patients

Vantive builds on a 70-year legacy of kidney care leadership and innovation, with a singular focus on empowering patients and care teams with more flexible, collaborative and accessible care options